PLSI - Phoenix Life Sciences International Limited

Other OTC - Other OTC Delayed Price. Currency in USD
21.00
0.00 (0.00%)
At close: 9:47AM EST
Stock chart is not supported by your current browser
Previous Close21.00
Open21.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range21.00 - 21.00
52 Week Range16.00 - 29.00
Volume55
Avg. Volume228
Market Cap641.548M
Beta (3Y Monthly)8.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire2 days ago

    Phoenix Life Sciences International Is Now Accepting Bids for Hemp CBD Producers and Manufacturers

    Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it is now accepting bids from U.S. licensed producers of industrial hemp to supply various products to be used in the formulation of its botanical pharmaceuticals. “As we move forward with our mission of transforming the future of global healthcare, our next step is partnering with a GMP licensed hemp producers in the U.S. that shares our values and mission to push botanical pharmaceuticals forward throughout the world,” said Phoenix Life CEO Martin Tindall. Phoenix Life is seeking a Good Manufacturing Practice (GMP) licensed industrial hemp partner for both U.S. and foreign markets to commence in January 2019.

  • GlobeNewswire8 days ago

    Phoenix Life Sciences International Announces the Release of the Company’s Investor Relations Deck and Accompanying Video Presentation

    Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it has released an online version of its Investor Relations deck with an accompanying video presentation on its website and at http://phxlife.net/PLSI-Deck. During the presentation video, Phoenix Life CEO Martin Tindall walks prospective investors through the company’s background, overall mission, business model, future plans and information on how to invest in Phoenix Life’s goal of transforming the future of global healthcare. “We are excited to release our Investor Relations deck and video presentation on our company website to provide investors in the public markets with a clear understanding of the business of Phoenix Life, our mission and our objectives,” said Phoenix Life Sciences International CEO Martin Tindall.

  • GlobeNewswire16 days ago

    Phoenix Life Sciences International Announces Angus Stewart as Company’s New Agriculture and Horticulture Senior Advisor

    Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Angus Stewart has joined the company as the Agriculture and Horticulture Senior Advisor. Angus Stewart has over two decades of experience specializing in horticulture and is currently an Agricultural and Horticultural Scientist and Consultant Plant Breeder of approximately 100 commercially released plant cultivars. Additionally, Stewart has extensive experience with plant breeding techniques of all levels and is well versed in the best practices for the production and extraction of botanical active ingredients like cannabinoids.

  • GlobeNewswirelast month

    Phoenix Life Sciences Receives Import Certificate for Cannabis Diabetes Drug from the Republic of Vanuatu

    Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it has received an import certificate from the Republic of Vanuatu’s Minister of Health to bring its cannabis diabetes drug Phoenix Metabolic into the country for clinical trials. “With this certificate, we look forward to playing a pivotal role in decreasing the size of the global diabetes epidemic,” said Phoenix Life Sciences International CEO Martin Tindall. Phoenix Life can now import its cannabis-based diabetes drug into Vanuatu and the company hopes to soon announce the launch of clinical trials for its first 1,000 patients.

  • GlobeNewswirelast month

    Phoenix Life Sciences International Announces Significant Retirement of Convertible Debt and Elimination of Outstanding Preferred Shares

    Phoenix Life Sciences International Limited (“Phoenix Life”) (PLSI), an international adaptive healthcare solutions company, today announced that it has retired additional convertible debt, positioning the company with no more outstanding preferred shares or debt that is subject to conversion. As a part of the implementation of its fiscal policy aimed at bringing shareholders value and forwarding the company's mission of creating a global platform for plant-based pharmaceuticals, including bringing medical cannabis products into the mainstream of healthcare, the company has retired its outstanding Series C debt and canceled its Series A and B. “To operate under the umbrella company Phoenix Life Sciences International, we executed the consolidation of various entities and focused on eliminating as much expensive debt as possible,” said Martin Tindall, Chief Executive Officer of Phoenix Life Sciences International.